This observation is intriguing in light of the growing number of studies employing HDAC inhibitor administration to enhance performance in memory and learning tests and in the (partial) reversal of phenotypes associated with different neurological disorders and diseases including autism, epilepsy, deafness and SMA37–43. Here, HDAC9 is linked to deafness.